147 related articles for article (PubMed ID: 22145063)
1. Predictors of malignancy in pancreatic head mass: a prospective study.
Sivaraman A; Muthukrishnan A; Boopathy Senguttvan N; Anil Suchak S; Kannan U
Pan Afr Med J; 2011; 9():30. PubMed ID: 22145063
[TBL] [Abstract][Full Text] [Related]
2. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
3. Preoperative Platelet-Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis.
Rammohan A; Cherukuri SD; Palaniappan R; Perumal SK; Sathyanesan J; Govindan M
World J Surg; 2015 Sep; 39(9):2323-8. PubMed ID: 25917199
[TBL] [Abstract][Full Text] [Related]
4. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.
Jin X; Wu Y
Afr Health Sci; 2015 Mar; 15(1):123-30. PubMed ID: 25834540
[TBL] [Abstract][Full Text] [Related]
6. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis.
Tessler DA; Catanzaro A; Velanovich V; Havstad S; Goel S
Am J Surg; 2006 Feb; 191(2):191-7. PubMed ID: 16442944
[TBL] [Abstract][Full Text] [Related]
7. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
[TBL] [Abstract][Full Text] [Related]
8. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
[TBL] [Abstract][Full Text] [Related]
9. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients.
Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P
Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902
[TBL] [Abstract][Full Text] [Related]
10. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
11. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
12. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
Kim JE; Lee KT; Lee JK; Paik SW; Rhee JC; Choi KW
J Gastroenterol Hepatol; 2004 Feb; 19(2):182-6. PubMed ID: 14731128
[TBL] [Abstract][Full Text] [Related]
14. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
Santander C; Jiménez I; Martín E; Melón A; Pajares JM
Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
[TBL] [Abstract][Full Text] [Related]
15. Predictors of malignancy in chronic calcific pancreatitis with head mass.
Perumal S; Palaniappan R; Pillai SA; Velayutham V; Sathyanesan J
World J Gastrointest Surg; 2013 Apr; 5(4):97-103. PubMed ID: 23717745
[TBL] [Abstract][Full Text] [Related]
16. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
18. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.
Molina V; Visa L; Conill C; Navarro S; Escudero JM; Auge JM; Filella X; Lopez-Boado MA; Ferrer J; Fernandez-Cruz L; Molina R
Tumour Biol; 2012 Jun; 33(3):799-807. PubMed ID: 22203495
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer.
Urgell E; Puig P; Boadas J; Capellà G; Queraltó JM; Boluda R; Antonijuan A; Farré A; Lluís F; González-Sastre F; Mora J
Eur J Cancer; 2000 Oct; 36(16):2069-75. PubMed ID: 11044643
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
